Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEO accession GSE287183 is currently private and is scheduled to be released on Jan 14, 2029.

ABSTRACT: GEO accession GSE287183 is currently private and is scheduled to be released on Jan 14, 2029.

PROVIDER: PRJNA1211564 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic de-repression of drivers of neuroendocrine prostate cancer [RNA-seq]

Project description:Epigenetic de-repression of drivers of neuroendocrine prostate cancer

2025-07-25 | GSE287183 | GEO

Epigenetic de-repression of drivers of neuroendocrine prostate cancer [CUT&Run]

Project description:Epigenetic de-repression of drivers of neuroendocrine prostate cancer

2025-07-25 | GSE287182 | GEO

Epigenetic de-repression of drivers of neuroendocrine prostate cancer [CUT&Run]

Project description:Epigenetic de-repression of drivers of neuroendocrine prostate cancer [CUT&Run]

| PRJNA1211567 | ENA

Neuroendocrine prostate cancer models

Project description:Neuroendocrine prostate cancer models

| PRJNA449097 | ENA

RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 2

Project description:Increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost androgen receptor (AR) signaling. AVPC tumors may also express neuroendocrine markers, termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing AR-negative to AR-positive prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-negative cell lines. Clinical NEPC and NEPC patient derived xenografts displayed upregulated RET transcript and RET pathway activity. Pharmacologically inhibiting RET kinase in NEPC models dramatically reduced tumor growth and cell viability in mouse and human NEPC models. Our results suggest that targeting RET in NEPC tumors with high RET expression may be a novel treatment option.

2020-05-29 | PXD012971 | Pride

RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 1

2020-05-29 | PXD012970 | Pride

Epigenomic profiling of neuroendocrine prostate cancer and prostate adenocarcinoma xenografts

Project description:We profiled the epigenomes of neuroendocrine prostate cancer and prostate adenocarcinoma patient-derived xenografts using ChIP-seq for transcription factors and histone modifications.

2020-11-22 | GSE161948 | GEO

ERRγ impedes neuroendocrine prostate cancer development [RNA-Seq]

Project description:Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (CRPC). The molecular mechanisms underlying the progression of CRPC toward NEPC remain incompletely understood and effective treatments remain to be discovered. Herein, we report that loss of the nuclear receptor ERRγ promotes neuroendocrine differentiation in a Pten-deficient mouse model of prostate adenocarcinoma. These findings were recapitulated in advanced cellular and xenograft models of human prostate cancer (PCa). Critically, we show that ERRγ gain-of-function can reverse instilled NEPC features accompanied by suppression of growth and oncogenic metabolic reprogramming. Activation of a neuroendocrine transcriptional program enabled by ERRγ deficiency unveiled a targetable vulnerability exploited by combined pharmacological inhibition of EZH2 and RET kinase that effectively inhibited the growth of ERRγ-deficient tumor organoids and cells. Collectively, our findings demonstrate that ERRγ downregulation facilitates PCa adeno-to-neuroendocrine transformation and offer potential therapeutic strategies to prevent/treat the development of poor outcome NEPC.

2025-10-29 | GSE248844 | GEO

ERRγ impedes neuroendocrine prostate cancer development [ChIP-Seq]

2025-10-29 | GSE291072 | GEO

ERRγ impedes neuroendocrine prostate cancer development

Project description:ERRγ impedes neuroendocrine prostate cancer development

| PRJNA1051044 | ENA